Telehealth Narcolepsy Prescribing: What Psychiatric NPs Can Do in Michigan

If you’re a psychiatrist or PMHNP considering treating narcolepsy patients through telehealth, you’re likely asking: Can I even do this legally? The answer isn’t simple—it depends on your credentials, your state, and which medications you’re prescribing. This isn’t about some fringe condition, either. Roughly 160,000 Americans live with narcolepsy, and many can’t access specialized care locally. That’s where you come in.

Here’s the reality: psychiatrists (MD/DO) can prescribe narcolepsy medications via telehealth in virtually every state, subject to federal controlled substance rules and a few state quirks. PMHNPs face a patchwork—in some states, you’ll have nearly the same authority as an MD after gaining experience; in others, you’ll need physician collaboration or face hard limits on Schedule II stimulants. Either way, there’s real demand for providers who understand both the clinical nuances and regulatory maze of narcolepsy treatment.

This guide breaks down what psychiatrists and PMHNPs can actually prescribe for narcolepsy via telehealth, which states make it easy (or painful), and what the economics look like when you’re managing controlled substances remotely. We’ll also tackle the practical headaches—prior authorizations, medication shortages, and the 7-day prescription limits that turn monthly refills into weekly admin nightmares in some states.

What Makes Narcolepsy Different from Your Typical Psych Prescribing

Narcolepsy isn’t depression or anxiety—it’s a neurological sleep disorder that forces providers into Schedule II stimulant territory (Adderall, Ritalin) or Schedule IV wakefulness agents (modafinil, armodafinil). Unlike managing ADHD where you might taper or switch easily, narcolepsy patients often need higher doses, longer treatment duration, and sometimes polypharmacy (stimulants during the day, sodium oxybate at night for cataplexy).

The clinical challenge? Most psychiatrists have limited narcolepsy experience—it affects about 1 in 2,000 people, so you might see only a handful in your career. Patients usually arrive with a sleep study already done (polysomnography with multiple sleep latency test), which means you’re not diagnosing from scratch—you’re managing medications and monitoring side effects. But that’s where telehealth shines: these patients need monthly check-ins for prescription refills (Schedule II rules), brief med adjustments, and safety monitoring (blood pressure on stimulants). A 15-minute video visit handles that beautifully, and you can see patients across state lines if you’re multi-licensed.

The regulatory wrinkle? Narcolepsy treatment requires navigating federal DEA rules for controlled substances plus state-specific telehealth and scope-of-practice laws. During COVID, the DEA suspended the Ryan Haight Act’s in-person exam requirement for Schedule II prescribing, and that flexibility has been extended through at least the end of 2025. After that? Providers might need to arrange initial in-person exams or hope Congress makes the waiver permanent. For now, you can initiate stimulants via pure telehealth in most states—but ‘most’ isn’t ‘all.’

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Psychiatrist Authority: What You Can Prescribe and Where

Psychiatrists (MD/DO) have unrestricted prescriptive authority for narcolepsy medications in all 50 states—with one asterisk. You’re licensed physicians; you can prescribe Schedule II–V controlled substances as long as you hold a DEA registration, are licensed in the patient’s state, and follow that state’s telehealth rules.

The federal baseline (as of 2026): Under the extended COVID-era waiver, you can conduct an initial video evaluation and prescribe a Schedule II stimulant like Adderall without ever seeing the patient in person. This applies nationwide. Once the waiver expires—potentially late 2025—new DEA rules may kick in requiring an in-person exam within 30 days of the first controlled substance prescription. Platforms and providers are already planning workarounds: partnering with local physicians for one-time in-person visits, or advocating for permanent telemedicine allowances (which makes sense given telehealth’s success during the pandemic).

State-Specific Psychiatrist Considerations

Most states align with federal law and impose no additional barriers for physicians prescribing narcolepsy meds via telehealth. But a few outliers matter:

Florida is the big one. Florida law (Fla. Stat. 456.47) prohibits prescribing Schedule II controlled substances via telehealth unless it’s for a psychiatric disorder, inpatient care, hospice, or chronic pain management. Narcolepsy isn’t a psychiatric disorder—it’s neurological—so technically, a Florida psychiatrist can’t initiate Adderall for narcolepsy purely via telehealth under state law. In practice, many providers work around this by using Schedule IV alternatives (modafinil, armodafinil) for telehealth patients, or ensuring at least one in-person visit if a Schedule II stimulant is required. The federal waiver might preempt Florida’s state restriction temporarily, but it’s legally gray.

Texas doesn’t restrict physician prescribing via telehealth, but you’ll need to ensure the practitioner-patient relationship meets Texas Medical Board standards (video-based, sufficient for the condition, documented). Texas psychiatrists can fully manage narcolepsy remotely—no special in-person requirement beyond federal rules.

California, New York, Illinois, Pennsylvania—all allow psychiatrists to prescribe controlled substances via telehealth with no state-imposed in-person visit requirements (beyond what federal law mandates). These states have robust telehealth parity laws, meaning insurance pays the same rate for video visits as in-person. They also require e-prescribing of controlled substances and PDMP (prescription drug monitoring program) checks before every Schedule II script—but that’s standard practice anyway.

Practical Workflow for Psychiatrists

You’ll typically do an initial 30-minute video evaluation: confirm the narcolepsy diagnosis (review sleep study reports or referral from a sleep specialist), review medical history (cardiac status is key—stimulants can raise BP and heart rate), obtain informed consent, and check the state PDMP. Then you e-prescribe the medication through a DEA-compliant system.

Follow-ups are monthly initially (driven by Schedule II 30-day supply limits), then quarterly once stable. You’ll bill E/M codes (99213/99214 for established patients), which typically reimburse $80–$130 per visit depending on payer and locality. Over a year, a single narcolepsy patient might generate $1,000–$1,500 in revenue—modest per patient, but multiply that across a full panel of telehealth patients you can see efficiently (no commute, no office overhead), and the economics work.

Key compliance steps every visit:

• Verify patient identity and location (licensure requirement)
• Document Epworth Sleepiness Scale or symptom scores
• Check state PDMP (mandatory in most states for every controlled Rx)
• Review medication adherence and side effects
• E-prescribe via EPCS-enabled system (no paper scripts)
• Document thoroughly (telehealth notes must meet same standard-of-care as in-person)

The biggest headache? Prior authorizations for newer meds like Sunosi (solriamfetol) or Wakix (pitolisant)—insurers want sleep study documentation and proof you tried older stimulants first. That’s 30–60 minutes of unpaid admin time per patient. And then there’s the Adderall shortage (ongoing since 2022), which forces frequent med switches and pharmacy hunting.

PMHNP Authority: Where You Can Practice Independently (and Where You Can’t)

Nurse practitioners have a completely different legal landscape. Your authority to prescribe narcolepsy medications depends entirely on your state’s scope-of-practice laws and whether you’ve met experience thresholds for independent practice. Let’s break down the extremes:

Full (or Nearly Full) Practice States

New York: After 3,600 hours of practice experience (roughly two years), PMHNPs in NY can practice and prescribe completely independently—no written collaborative agreement required. You can prescribe Schedule II–V controlled substances on your own authority, including stimulants for narcolepsy. Before hitting that 3,600-hour mark, you’ll need a collaborative agreement with a physician that outlines your prescribing authority, but even then, you can prescribe stimulants under that protocol. All prescribers in NY must check the I-STOP PDMP before every controlled substance prescription and e-prescribe everything. Bottom line: experienced PMHNPs in NY function identically to psychiatrists for narcolepsy telehealth.

Illinois: Illinois grants Full Practice Authority (FPA) to NPs after 4,000 hours of clinical experience + 250 hours of continuing education. With FPA, you can prescribe all narcolepsy medications independently—stimulants, modafinil, even sodium oxybate (Schedule III). Illinois does impose two quirks: if you prescribe Schedule II narcotics (opioids), you must maintain a consultation relationship with a physician and document monthly discussions. And if you prescribe benzodiazepines beyond 120 days continuously, you need a physician consult. But stimulants for narcolepsy? Not covered by either rule—you’re fully independent. Before FPA, you’ll need a written collaborative agreement with a physician who delegates controlled substance prescribing to you by name in the protocol.

California: CA is transitioning to independent NP practice under AB 890. As of 2023, NPs can work as ‘103 NPs’ in group settings with at least one physician (no individualized supervision on each act). After 3 years or 4,600 hours as a 103 NP, you can apply for ‘104 NP’ status starting in 2026—that’s full independence. Once you’re a 104 NP, you can open your own practice and prescribe stimulants for narcolepsy without any physician involvement. Until then, you’ll operate under standardized procedures with a physician collaborator. CA allows NPs to prescribe Schedule II–V drugs (including narcolepsy meds), but historically required extra pharmacology coursework and patient-specific protocols for Schedule IIs—AB 890’s implementation likely integrates those requirements into the new pathway.

Restricted Practice States

Texas: This is the toughest state for NPs treating narcolepsy. Texas requires all NPs to have a Prescriptive Authority Agreement (PAA) with a physician—no exceptions for independent practice. Worse, Texas law prohibits NPs from prescribing Schedule II controlled substances for outpatient care, except in narrow cases (hospital inpatient orders, hospice). That means a Texas PMHNP cannot prescribe Adderall or Ritalin for an outpatient narcolepsy patient in a clinic or telehealth setting. Only a physician can write those prescriptions.

You can prescribe Schedule III–V meds (modafinil is Schedule IV), up to a 90-day supply with physician oversight. But for most narcolepsy patients who need stimulants, you’ll have to partner with a collaborating physician who writes the Schedule II prescriptions while you handle follow-up care. In practice, this means Texas NPs in telehealth need an MD teammate—not ideal if you’re trying to practice independently.

Florida: Florida requires physician collaborative agreements for PMHNPs (psychiatric NPs were explicitly excluded from the state’s 2020 autonomous NP law). Florida APRNs can prescribe Schedule II drugs, but only in 7-day supply increments for adults—unless you’re a certified ‘psychiatric nurse’ prescribing for a psychiatric disorder, in which case the 7-day limit doesn’t apply. But narcolepsy isn’t a psychiatric disorder, so even a PMHNP in Florida would be bound by that 7-day limit for stimulants. That’s four separate prescriptions to cover one month—massively burdensome.

Florida also mirrors the Schedule II telehealth ban mentioned earlier: you can’t prescribe Schedule IIs via telemedicine unless it’s for a psychiatric disorder (among other exceptions). A PMHNP treating narcolepsy in Florida faces a double whammy: restricted supply limits and state telehealth prohibitions on Schedule IIs. Most Florida PMHNPs rely on their collaborating psychiatrist to handle stimulant prescriptions directly.

Pennsylvania: PA requires PMHNPs to practice under a written collaborative agreement with a physician. You can prescribe Schedule II drugs, but only up to a 30-day supply (Schedule III–IV up to 90 days). Beyond that, you need physician approval. The 30-day limit aligns with typical stimulant management anyway (monthly visits for refills), so it’s workable—but you’ll never have true independence. Your collaborative physician’s name has to appear on prescriptions per state pharmacy rules, and you’ll need to notify them within 24 hours of writing a Schedule II script.

Pennsylvania has debated full practice authority bills repeatedly, but as of 2026, NPs still require physician collaboration. If you’re practicing narcolepsy telehealth in PA as a PMHNP, make sure your collaborative agreement explicitly covers stimulants and you’re compliant with state PDMP requirements.

The Bottom Line for PMHNPs

If you’re in NY, IL, or CA (and have the requisite experience), you can treat narcolepsy patients almost identically to a psychiatrist. If you’re in TX or FL, you’ll need a collaborative physician partner—and in TX, that physician will have to write the Schedule II prescriptions themselves. Pennsylvania sits in the middle: you can prescribe stimulants under supervision with quantity limits.

State-by-State PMHNP Prescribing Authority Summary

The Economics: Patient Acquisition, Reimbursement, and ROI

Let’s talk money—because if the clinical and legal pieces work, you still need this to be financially viable.

Patient Acquisition: Why Platform Models Win

Acquiring psychiatric patients through DIY marketing (SEO, Google Ads, directory listings) is expensive and uncertain. Here’s what that actually costs when you factor in all expenses:

SEO takes 6–12 months of consistent investment before generating meaningful patient flow. You’ll pay an agency $2,000–$5,000/month (or spend dozens of unpaid hours learning it yourself), test content and backlinks, and wait for Google to decide you’re credible. Even then, most psychiatric keywords are brutally competitive—hundreds of other providers chasing the same ‘psychiatrist near me’ searches.

Google Ads for mental health keywords run $15–$40+ per click. Most clicks don’t convert to booked patients (maybe 2–5% conversion rate if you’re lucky). To get one booked patient, you might burn through 30–50 clicks—that’s $450–$2,000 in ad spend per patient, plus monthly management fees if you’re hiring someone to run campaigns. And many of those leads will no-show or not be appropriate for your specialty.

Directory listings (Psychology Today, Zocdoc) charge monthly subscription fees ($30–$100+) and per-booking fees (Zocdoc charges $35–$100+ per patient lead, depending on specialty and location). You’re competing with hundreds of other providers on the same page, and conversion rates are unpredictable. Total monthly cost easily hits $500–$1,500 when you account for subscriptions, booking fees, and time spent managing profiles.

Reality check: When you add up agency fees, ad spend testing and optimization, staff time to handle and qualify leads, no-show rates from cold leads, and months of investment before results, acquiring a qualified psychiatric patient through traditional marketing typically costs $200–$500+—and that’s per patient, not per visit.

How Klarity Health’s Model Changes the Math

Klarity uses a pay-per-appointment model similar to Zocdoc, where providers pay a standard listing fee per new patient lead. But here’s the difference:

No upfront marketing spend: You’re not gambling $3,000–$5,000/month on SEO or PPC campaigns that might not work. You pay nothing until a qualified patient books with you.

Pre-qualified patients: Leads are already matched to your specialty (psychiatry or PMHNP), availability, and patient needs. No wasted time screening inappropriate referrals or managing ad campaigns that attract tire-kickers.

Built-in telehealth infrastructure: You’re not paying separately for a video platform ($50–$200/month for secure HIPAA-compliant systems like Doxy or SimplePractice). E-prescribing, scheduling, billing support—it’s included.

Both insurance and cash-pay patients: You get patient flow from both channels, expanding your potential volume beyond what one marketing channel could deliver.

You control your schedule: Only pay when you see patients. If you need to scale back, you’re not locked into monthly retainer fees for marketing agencies or ad spend commitments.

The economic framing is simple: instead of spending thousands per month on marketing with uncertain results (and no guarantee those patients will book or show up), you pay a known fee per patient you actually see. That’s guaranteed ROI versus gambling on marketing channels. For narcolepsy specifically—where patients need monthly follow-ups for refills—one acquired patient generates recurring revenue. If a patient stays with you for a year of monthly visits at $100–$130 per visit (insurance reimbursement), that’s $1,200–$1,560 in total revenue. Paying a listing fee to acquire that patient is a no-brainer compared to burning $500+ on failed ad campaigns.

Reimbursement Reality for Psychiatrists vs PMHNPs

Psychiatrists bill E/M codes (99213/99214 for follow-up med checks), which typically reimburse $80–$130 per visit depending on payer and locality. Private insurance pays similarly to in-person visits due to telehealth parity laws in most states. Medicare pays the same for tele-mental health as in-person (at least through 2024, likely extended beyond), though there’s a looming rule requiring an in-person visit every six months unless Congress acts.

One pain point: mental health providers are paid ~22% less by private insurers on average compared to other physicians (per an RTI analysis cited by Axios). This disparity—a mental health parity law compliance issue—drives many psychiatrists out-of-network. But narcolepsy management sometimes gets coded as a neurological condition (ICD-10 G47.4x), which might route through medical benefits and avoid some behavioral health reimbursement caps. Worth exploring with your billing team.

PMHNPs face another wrinkle: Medicare reimburses nurse practitioners at 85% of the physician fee schedule when billing under their own NPI. So if a psychiatrist gets $100 for a 99213, an NP gets $85. Private insurers historically paid NPs and MDs equally for in-network services, but some payers are adopting similar differential rates. In states with payment parity laws (Illinois, New York, California), this gap is narrowing for telehealth services.

Prior authorizations remain the unpaid time-suck. Narcolepsy medications—especially newer agents like Sunosi, Wakix, or sodium oxybate—often require PA with sleep study documentation. That’s 30–60 minutes per patient of paperwork you can’t bill for. Some platforms (hint) have admin support staff to handle PA submissions, which removes that burden and improves your effective hourly rate.

Cash-pay models are increasingly popular for telehealth: charge $100–$150 per 15-minute follow-up visit, and patients pay directly. No insurance hassles, no PA headaches, no claim denials. For narcolepsy patients desperate for specialized care and facing months-long wait times for local sleep specialists, many will pay out-of-pocket. This also eliminates the reimbursement gap between MDs and NPs—you set your own rate.

Volume and Efficiency

Telehealth lets you see more patients per hour by eliminating commute time, reducing no-shows (patients join from home), and streamlining workflows. A psychiatrist conducting 15-minute narcolepsy med checks via video could realistically see 3–4 patients per hour. At $100 average reimbursement per visit, that’s $300–$400/hour in gross revenue. Even accounting for platform fees and taxes, your net is substantially higher than traditional in-person practice with its overhead (office rent, front-desk staff, malpractice tail coverage for in-person visits).

For PMHNPs in full-practice states, you’re delivering the same service as an MD psychiatrist (clinically) at similar or slightly lower reimbursement rates—but with less debt from training. ROI on your time is excellent, especially if you’re multi-licensed and can see patients across several states from one location.

Practical Pain Points: What Nobody Tells You About Narcolepsy Telehealth

Let’s be real—treating narcolepsy via telehealth isn’t just clicking through video visits and e-prescribing stimulants. There are specific headaches you’ll face:

Confirming the diagnosis: Unlike depression or ADHD, which you can diagnose in-office, narcolepsy typically requires a sleep specialist-administered polysomnography with multiple sleep latency test (MSLT). Most patients arrive with that done, but if they don’t, you’re stuck referring them to a sleep lab (which can delay treatment by weeks) and hoping they follow through. Telehealth complicates this—you can’t just walk them down the hall to a sleep center. You’ll need referral networks or clear protocols for what you require before prescribing.

The Adderall shortage: Ongoing since mid-2022, the stimulant shortage has been brutal for narcolepsy patients. Pharmacies can’t fill prescriptions, forcing you to switch meds frequently or hunt for alternative pharmacies. A patient stable on Adderall for years suddenly can’t get it—leading to uncontrolled sleep attacks, which can be dangerous (falling asleep while driving). You’ll spend extra unpaid time coordinating switches to methylphenidate or modafinil, re-titrating doses, and fielding panicked calls when pharmacies are out of stock.

7-day prescription limits in states like Florida turn monthly refills into weekly admin. You’ll write four separate e-prescriptions every month, track when each needs to be sent, and deal with patient confusion (‘Why can’t I just get 30 days at once?’). It’s legally required, but it’s absurd from a workflow perspective.

PDMP checks every visit: Most states mandate checking the prescription drug monitoring program before each controlled substance prescription. That’s 2–5 minutes per patient—not a huge burden, but it adds up across dozens of patients. Some states (like New York) require documentation that you checked it in the patient’s chart every time.

Remote monitoring challenges: Stimulants can elevate blood pressure and heart rate. In an in-person practice, you’d check vitals at every visit. In telehealth, you’re relying on patients to use home BP cuffs or get labs done locally. Compliance isn’t always great, and coordinating with local PCPs for monitoring adds friction.

Stigma and advocacy: Narcolepsy patients face misunderstanding (‘just sleep more’) and employment/academic challenges. You’ll sometimes need to write letters for workplace accommodations or disability applications—unpaid advocacy work that’s part of comprehensive care but eats into your schedule.

Medication shortages and formulary restrictions: Beyond Adderall, sodium oxybate (Xyrem/Xywav) has a REMS program requiring special prescriber enrollment and a single central pharmacy. If you’re managing cataplexy, you’ll deal with that administrative maze. Newer agents like Wakix and Sunosi often aren’t on formulary, requiring step therapy (try cheaper stimulants first) before approval.

All of this is manageable—but it’s different from managing depression or anxiety. Narcolepsy treatment is higher-touch in terms of regulatory compliance and medication logistics, which is why having platform support (for PA coordination, PDMP integration, patient education resources) makes a material difference in your workload.

Why Platforms Beat Solo Practice for Narcolepsy Telehealth

If you’re a psychiatrist or experienced PMHNP considering whether to join a telehealth platform versus building your own practice, here’s the honest calculus:

Solo telehealth practice means you control everything—your rates, your schedule, your patient selection. But you also handle everything: building a website, SEO, PPC campaigns, credentialing with insurers, billing and collections, HIPAA-compliant infrastructure, EHR setup, PDMP integrations, e-prescribing systems, malpractice insurance, business licenses in every state you practice, continuing education for multi-state licensure… the list is endless. You’ll spend 20–30 hours per week on non-clinical admin just to keep the lights on, and it’ll take 6–12 months before you’re seeing a full patient panel.

Platform model (like Klarity Health) offloads almost all of that. You focus on clinical care; the platform handles patient acquisition, scheduling, billing, tech infrastructure, compliance monitoring, and often even PA support. You trade some autonomy (you’re seeing platform-referred patients, not building your own brand) for immediate patient flow, predictable income, and zero upfront marketing spend.

For narcolepsy specifically, the platform model is especially attractive because:

• Narcolepsy patients are hard to find organically—they’re only 0.05% of the population. A platform with national reach and targeted marketing can funnel these patients to you much faster than you’d attract them solo.
• Regulatory complexity (state-by-state prescribing rules, DEA compliance, PDMP checks) is handled by platform compliance staff who stay updated on law changes. You’re not scrambling to figure out whether Florida’s telehealth ban applies to your situation—someone else has already done that analysis.
• Multi-state licensure is expensive and time-consuming to maintain solo. Platforms often have streamlined processes or reimbursement for licensure costs, making it easier to scale across states.
• Patient retention is high in narcolepsy (monthly visits for refills), so once a platform refers a patient, you’re likely keeping them long-term—steady income with minimal churn.

The ROI comparison: if you’re spending $3,000–$5,000/month on marketing and hundreds of hours building a solo practice, your break-even point is 6–12 months out and uncertain. If you join a platform and pay per patient seen, you’re cash-flow positive from day one and can scale up or down based on your schedule. For mid-career providers who want to add telehealth income without the risk of a startup, platforms win. For newer PMHNPs who haven’t yet built a patient base, platforms are often the only viable path.

FAQ: Narcolepsy Telehealth Prescribing

Can a psychiatrist prescribe Adderall for narcolepsy via telehealth?
Yes, in most states. Under the extended federal DEA waiver (through at least end of 2025), psychiatrists can initiate Schedule II stimulants like Adderall via telehealth without an in-person exam. Exceptions: Florida’s state law restricts Schedule II telehealth prescribing for non-psychiatric conditions, so a Florida psychiatrist might need at least one in-person visit or use alternative meds. Always check your state’s specific telehealth controlled-substance rules.

Can a PMHNP prescribe narcolepsy medications independently?
It depends on your state and experience level. In full-practice states like New York (after 3,600 hours), Illinois (after 4,000 hours + CE), and California (after transitioning to 104 NP status in 2026), yes—you can prescribe narcolepsy stimulants independently. In restricted states like Texas, you cannot prescribe Schedule II stimulants for outpatients without a physician writing those prescriptions. Florida allows PMHNP prescribing but limits Schedule II to 7-day supplies. Pennsylvania requires physician collaboration with 30-day supply limits on Schedule IIs.

Do I need a sleep study to prescribe narcolepsy medications?
Standard of care is yes—narcolepsy diagnosis typically requires polysomnography with MSLT (multiple sleep latency test) confirming excessive daytime sleepiness and rapid REM onset. Most patients arrive with this documentation already. If they don’t have it, you’ll need to refer them to a sleep specialist for testing before initiating controlled stimulants, as prescribing without confirmed diagnosis is medicolegally risky.

What’s the reimbursement for narcolepsy medication management visits?
For psychiatrists: typically $80–$130 per 15–20 minute follow-up visit (99213/99214 codes), depending on payer and location. Telehealth parity laws in most states ensure video visits reimburse at the same rate as in-person. For PMHNPs: Medicare reimburses at 85% of the physician rate; private payers vary but often pay equally in states with payment parity laws. Monthly visits for stimulant refills generate $1,000–$1,500+ per patient annually in reimbursement.

How do I handle the Adderall shortage when treating narcolepsy patients?
The shortage (ongoing since 2022) requires flexibility: be prepared to switch patients to methylphenidate (Ritalin), modafinil, or armodafinil if Adderall is unavailable. Build relationships with multiple pharmacies so you can reroute prescriptions quickly. Communicate proactively with patients about supply issues and have backup medication plans in place. Document everything—insurance sometimes requires explanation for off-formulary switches.

What are the PDMP requirements for prescribing narcolepsy stimulants?
Almost all states require checking the prescription drug monitoring program (PDMP) before prescribing controlled substances. Frequency varies: some states require a check before every controlled Rx (New York), others allow periodic review (e.g., quarterly for established patients). Most telehealth EHR systems integrate PDMP access, so you can check in-session. Document each check in the patient’s chart—it’s a compliance requirement and malpractice protection.

Can I prescribe sodium oxybate (Xyrem/Xywav) via telehealth?
Yes, but it requires extra steps. Sodium oxybate is Schedule III with a REMS program—you must enroll as a certified prescriber, and the medication is dispensed through a single central pharmacy. You can conduct the clinical evaluation and ongoing management via telehealth, but the patient will receive the medication via mail/courier from the REMS pharmacy, not a local pharmacy. This adds coordination complexity but is definitely doable remotely.

What happens if the DEA ends the telehealth prescribing waiver in 2026?
If the waiver expires without a permanent solution, providers would need to conduct an initial in-person exam before prescribing Schedule II controlled substances. Platforms and providers are preparing for this by establishing partnerships with local clinicians for one-time in-person visits, or by advocating for Congress to make the telehealth allowance permanent. Many expect an extension or permanent rule given telehealth’s proven safety and access benefits during COVID.

Ready to Treat Narcolepsy Patients via Telehealth?

If you’re a psychiatrist or PMHNP looking to expand into narcolepsy care through telehealth, the clinical need is real—and the regulatory path is clearer than you might think. Psychiatrists have broad authority (with a few state quirks). PMHNPs in full-practice states can operate at near-parity, while those in restricted states need collaborative partnerships.

The economics make sense when you’re not burning thousands per month on uncertain marketing. Platforms that handle patient acquisition, compliance, and infrastructure let you focus on clinical care while building steady income from recurring monthly visits.

At Klarity Health, we’ve built a telehealth platform that supports psychiatrists and PMHNPs in treating specialty conditions like narcolepsy—handling patient matching, regulatory compliance, e-prescribing infrastructure, PDMP integration, and prior authorization support so you can focus on medication management and patient care. We operate in multiple states, credential providers efficiently, and connect you with patients who need your expertise.

Interested in joining our network? Explore Klarity Health’s provider opportunities to learn more about how we support narcolepsy telehealth prescribing with compliant workflows, multi-state licensure support, and a steady flow of patients who need specialized psychiatric care.

Citations and Sources

All regulatory and clinical information in this guide has been verified against primary sources. Below are the key references used, with publication dates and reliability notes:

1. Axios – ‘COVID-era telehealth prescribing extended again’ (Nov 18, 2024) – Reports DEA/HHS extension of controlled-substance telehealth allowances through end of 2025. Source

2. Texas Medical Board – FAQ on Schedule II delegation (Accessed 2025) – Official guidance confirming Texas NP/PA Schedule II prescribing limited to hospital/hospice

Source:

• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20and,person%20doctor%27s%20visit%20for%20the
• https://natlawreview.com/article/new-florida-law-allows-telemedicine-prescribing-controlled-substances#:~:text=controlled%20substances%20via%20telemedicine%2C%20with,more%20on
• https://www.ilga.gov/legislation/ILCS/details?ActID=1312&ActName=Nurse+Practice+Act.&ChapAct=225+ILCS+65%2F&Chapter=&ChapterID=24&MajorTopic=&Print=True&SeqEnd=17850000&SeqStart=16500000#:~:text=,drugs%2C%20such%20as
• https://www.ilga.gov/legislation/ILCS/details?ActID=1312&ActName=Nurse+Practice+Act.&ChapAct=225+ILCS+65%2F&Chapter=&ChapterID=24&MajorTopic=&Print=True&SeqEnd=17850000&SeqStart=16500000#:~:text=,require%20a%20physician%20name%3B
• https://www.rivkinrounds.com/2022/04/new-law-allows-experienced-nps-to-practice-independently-in-ny/#:~:text=New%20York%E2%80%99s%202023%20state%20budget%2C,practice%20without%20a%20collaborative%20relationship
• https://www.rn.ca.gov/practice/ab890.shtml#:~:text=%2A%20103%20NP%20,focus%20of%20their%20National%20Certification
• https://www.rn.ca.gov/practice/ab890.shtml#:~:text=Please%20note%2C%20the%20law%20requires,certify%20104%20NPs%20until%202026
• https://www.tmb.state.tx.us/274-who-can-prescribe-schedule-ii-drugs-under-physician-delegation#:~:text=1.%20in%20a%20hospital%20facility,has%20elected%20to%20receive%20hospice
• https://www.flsenate.gov/Laws/Statutes/2021/Chapter464/All#:~:text=match%20at%20L1566%20limit%20the,455
• https://www.pacodeandbulletin.gov/Display/pacode?file=%2Fsecure%2Fpacode%2Fdata%2F049%2Fchapter21%2Fs21.284.html#:~:text=,may%20not%20delegate%20prescriptive%20authority